How many drugs treat Menopausal flushing?

Drug Landscape tracks 10 marketed treatments for Menopausal flushing (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Menopausal flushing?

Most recent: Estring — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/menopausal-flushing.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Menopausal flushing — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Menopausal flushing (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Menopausal flushing, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Slynd	DROSPIRENONE	Exeltis Usa Inc	Progestin	Mineralocorticoid receptor	2019-01-01
Duavee	BAZEDOXIFENE	Wyeth Pharms Pfizer	Estrogen [EPC]	estrogen receptors (ER) α and β	2013-01-01
Depoestradiol	ESTRADIOL CYPIONATE	Pfizer	Estrogen	Estrogen receptor beta	1979-01-01
Testosterone Cypionate	Testosterone Cypionate	Azurity	Androgen	Androgen receptor	1978-01-01
Estrace	ESTRADIOL	Pfizer	Estrogen	Estrogen receptor	1975-01-01
Testred	METHYLTESTOSTERONE	Bausch Health	Androgen [EPC]	Androgen receptor	1973-01-01
Androgel	TESTOSTERONE	Besins Hlthcare	Androgen [EPC]	Androgen receptor	1972-01-01
Jadelle	LEVONORGESTREL	Fdn Consumer	Progestin	Progesterone receptor	1968-01-01
Micronor	norethisterone	Johnson & Johnson	Progestin	GnRH receptors	1962-01-01
Delestrogen	ESTRADIOL VALERATE	Ph Health	Estrogen	Estrogen receptor	1954-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-11 — Estring · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 5 drugs in Menopausal flushing
Bausch Health · 1 drug in Menopausal flushing
Besins Hlthcare · 1 drug in Menopausal flushing
Endo · 1 drug in Menopausal flushing
Exeltis Usa Inc · 1 drug in Menopausal flushing
Fdn Consumer · 1 drug in Menopausal flushing
Ferring · 1 drug in Menopausal flushing
Gulhane School of Medicine · 1 drug in Menopausal flushing
Johnson & Johnson · 1 drug in Menopausal flushing
Leticia Maria Defendi Barboza Marson · 1 drug in Menopausal flushing
Merck & Co. · 1 drug in Menopausal flushing
Minia University · 1 drug in Menopausal flushing

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Menopausal flushing:

Cite this brief

Drug Landscape (2026). Menopausal flushing — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/menopausal-flushing. Accessed 2026-06-10.

Menopausal flushing full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing